The bidirectional relationship between anxiety disorders and circulating levels of inflammatory markers: Results from a large longitudinal population-based study. by Glaus, J. et al.
   
 
 
 
 
Serveur Acade´mique Lausannois SERVAL serval.unil.ch
Author Manuscript
Faculty of Biology and Medicine Publication
This paper has been peer-reviewed but does not include the final publisher
proof-corrections or journal pagination.
Published in final edited form as:
Title: The bidirectional relationship between anxiety disorders and
circulating levels of inflammatory markers: Results from a large
longitudinal population-based study.
Authors: Glaus J, von Ka¨nel R, Lasserre AM, Strippoli MF, Vandeleur
CL, Castelao E, Gholam-Rezaee M, Marangoni C, Wagner EN,
Marques-Vidal P, Waeber G, Vollenweider P, Preisig M, Merikangas KR
Journal: Depression and anxiety
Year: 2017
DOI: 10.1002/da.22710
In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains
an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article.
Glaus - 1 
 
The bidirectional relationship between anxiety disorders and circulating levels of 
inflammatory markers: results from a large longitudinal population-based study  
Running title: Anxiety disorders and inflammation 
Jennifer Glaus
1,2
, Roland von Känel
3,4
, Aurélie M Lasserre
1
, Marie-Pierre F Strippoli
1
, Caroline L 
Vandeleur
1
, Enrique Castelao
1
, Mehdi Gholam-Rezaee
1
, Ciro Marangoni
2
, En-Young N Wagner
4
, Pedro 
Marques-Vidal
5
, Gérard Waeber
5
, Peter Vollenweider
5
, Martin Preisig
1
 and Kathleen R Merikangas
2
 
1
  Psychiatric Epidemiology and Psychopathology Research Center, Lausanne University Hospital, 
Department of Psychiatry, Switzerland. 
2
  Genetic Epidemiology Research Branch, Intramural Research Program, National Institute of Mental 
Health, Bethesda, MD, USA. 
3
  Department of Psychosomatic Medicine, Clinic Barmelweid, Barmelweid, Switzerland. 
4  
Department of Neurology, Inselspital, Bern University Hospital, and University of Bern, Switzerland. 
5
  Department of Internal Medicine, Lausanne University Hospital, Switzerland. 
 
Corresponding author: Jennifer Glaus, Genetic Epidemiology Research Branch, Intramural Research 
Program, National Institute of Mental Health, 35 Covent Drive, MSC 3720, Bldg 35A, Room 2E422A, 
Bethesda, MD 20892, Phone: +1 (301) 435-2206, Fax: +1 (301) 480-0278, jennifer.glaus@nih.gov 
 
Keywords: anxiety disorders, agoraphobia, social phobia, panic disorder, cytokines, C-Reactive Protein, 
body mass index. 
 
 
 
Page 1 of 26 Depression and Anxiety
Glaus - 2 
 
CONFLICT OF INTEREST DISCLOSURE AND FINANCIAL SUPPORT 
P. Vollenweider, G. Waeber and M. Preisig received two unrestricted grants from GlaxoSmithKline 
Clinical Genetics to build the CoLaus|PsyCoLaus study. J. Glaus received support from the Swiss National 
Science Foundation and from the Intramural Research Program of the National Institute of Mental 
Health through a Visiting Fellowship. A. Lasserre received support from the Swiss National Science 
Foundation. The remaining authors report no biomedical financial interests or potential conflicts of 
interest. 
 
  
Page 2 of 26Depression and Anxiety
Glaus - 3 
 
ABSTRACT 
Background: Whereas there has been abundant research on chronic low-grade inflammation as a 
potential mechanism underlying the link between mood disorders and cardiovascular risk, less is known 
about the role of inflammatory factors and anxiety disorders. The aim of this paper is to evaluate the bi-
directional associations between inflammatory markers including Interleukin (IL)-6, Tumor Necrosis 
Factor (TNF)-α and high sensitivity C-reactive protein (hsCRP) with anxiety disorders and its subgroups.  
Methods: The sample consisted of 3,113 participants (53.7% women; mean age: 51.0, s.d. 8.8 years), 
randomly selected from the general population, who underwent comprehensive somatic and psychiatric 
evaluations at baseline and follow-up (mean follow-up duration = 5.5 years, s.d. 0.6). Anxiety disorders 
were assessed with semi-structured diagnostic interviews. Inflammatory biomarkers were analyzed in 
fasting blood samples.  
Results: After adjustment for potential confounders, current anxiety disorders (β=0.09, 95%CI 0.00-0.17) 
and agoraphobia (β=0.25, 95% CI: 0.07-0.43) at baseline were associated with a steeper increase of 
hsCRP levels over the follow-up period. Current post-traumatic stress disorder (PTSD) was associated 
with a lower increase of IL-6 levels over the follow-up period (β=-0.52, 95% CI: -1.00/-0.04). There was 
no evidence for an association between inflammation markers at baseline and anxiety disorders at 
follow-up. 
Conclusions: The prospective association between agoraphobia at baseline and hsCRP levels over the 
follow-up period suggests that chronic low-grade inflammation may be a consequence of this condition. 
The decrease in IL-6 in PTSD also requires further investigation. No evidence was found for chronic low-
grade inflammation as a predictor of future anxiety disorders.  
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INTRODUCTION 
There is consistent evidence for a potent association between anxiety disorders and medical conditions, 
particularly cardiovascular risk factors (CVRFs) and diseases (CVD) (Furtado, & Katzman, 2015; Glaus et 
al., 2013; Tully, Cosh, & Baune, 2013; Van der Kooy et al., 2007). Medical comorbidity is associated with 
substantially greater disability than anxiety disorders alone (Furtado, & Katzman, 2015). Recent research 
has examined the role of chronic low-grade inflammation as a potential mechanism underlying the 
association between anxiety disorders and CVRFs/CVD (Furtado, & Katzman, 2015; Salim, Chugh, & 
Asghar, 2012). Insight into the role of inflammation in anxiety disorders could inform novel treatments 
and reduce the risk of anxiety disorders through the prevention of chronic inflammation. Compared to 
depression, studies on the role of the immune system in anxiety disorders are scarce, and it is still 
unclear to which degree chronic inflammation is implicated in their etiology and consequences (Furtado, 
& Katzman, 2015; Salim, Chugh, & Asghar, 2012; Turna, Grosman Kaplan, Anglin, & Van Ameringen, 
2016). Psychological stress related to anxiety disorders has been shown to dysregulate the 
hypothalamic-pituitary-adrenal (HPA) axis with an activation of the innate inflammatory response, 
evidenced by increases in Interleukin (IL)-1β, IL-6 and Tumor Necrosis Factor (TNF)-α, as well as the C-
Reactive Protein (CRP) (Furtado, & Katzman, 2015). Moreover, increased oxidative stress could lead to 
chronic activation of pro-inflammatory markers which could alter anxiety disorders, such as generalized 
anxiety disorder (GAD), social phobia and panic disorder (Salim, Chugh, & Asghar, 2012). 
Existing literature on the associations between aggregate anxiety disorders and specific subtypes 
thereof with increased inflammation is limited and comorbidity with other mental disorders has not 
always been taken into consideration (Gill, Saligan, Woods, & Page, 2009; Khandaker, Zammit, Lewis, & 
Jones, 2016; Liukkonen et al., 2011; Pitsavos et al., 2006; Turna, Grosman Kaplan, Anglin, & Van 
Ameringen, 2016; Vogelzangs, Beekman, de Jonge, & Penninx, 2013). With respect to specific subtypes 
of anxiety, the most consistent evidence has been found for increased levels of inflammatory markers 
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with post-traumatic stress disorder (PTSD) (Gill, Saligan, Woods, & Page, 2009; Spitzer et al., 2010; von 
Kanel et al., 2007). Moreover, a recent cross-sectional study of adolescents found an association 
between GAD and increased CRP levels (Khandaker, Zammit, Lewis, & Jones, 2016). Evidence for an 
association between inflammatory markers and obsessive-compulsive disorder (OCD) has also been 
found, even though results of a series of studies are inconsistent (Turna, Grosman Kaplan, Anglin, & Van 
Ameringen, 2016). Although previous research consistently shows increased levels of inflammation in 
anxiety disorders, longitudinal studies that can inform the ordinal patterns of inflammation with respect 
to the onset and recurrence of anxiety disorder subtypes are necessary to inform potential mechanisms 
for these associations. The only prospective study of inflammatory factors and anxiety in a community 
sample of youth showed a bidirectional association between GAD and CRP that was attenuated after 
controlling for the mediating effect of BMI and medication use (Copeland et al., 2012). Our previous 
analyses of inflammation and agoraphobia showed that a history of agoraphobia was associated with 
subsequent increase in CRP and TNF-α levels (Wagner et al., 2015).  
Accordingly, the aims of the present study were: (1) to evaluate the specificity of 5-year prospective 
associations between aggregate anxiety disorders and specific subtypes, (i.e., GAD, social phobia, panic 
disorder, agoraphobia, OCD and PTSD), and changes in circulating levels of specific inflammatory 
markers (IL-6, TNF-α, hsCRP); (2) to assess the directional associations between inflammatory markers 
and anxiety disorders and subtypes; (3) to examine whether the markers comprise state versus trait 
indices by comparing remitted versus current disorders, as well as incident cases; and (4) to examine the 
role of health behaviors, CVRFs, and treatment factors that may influence these associations. 
 
 
MATERIALS AND METHODS 
Study sample 
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The data of the present investigation were drawn from CoLaus|PsyCoLaus (Firmann et al., 2008; Preisig 
et al., 2009), a cohort study designed to prospectively assess the associations of mental disorders with 
CVD and CVRFs in the community. The sample was randomly selected from the civil register of the city 
of Lausanne (Switzerland) in 2003. Sixty-seven percent of the 35 to 66 year-old subjects (n = 5,535) who 
underwent the physical exam between 2003 and 2006 also participated in a psychiatric evaluation, 
which resulted in a sample of 3,719 individuals (Preisig et al., 2009) (see Figure 1, flow chart). Five years 
later, 3,191 participated in a follow-up physical exam (85.8% participation). Among these, 61 
participants were excluded due to missing information on inflammatory markers both at baseline and 
follow-up, 14 subjects were excluded due to missing information on mental disorders and 3 subjects 
were excluded due to missing information on CVRFs. The final sample used to examine associations 
between anxiety disorders at baseline and inflammation at follow-up consisted of 3,113 participants in 
total (53.7% women; mean age: 51.0, s.d. 8.8 years): 2,791 participants were analyzed for cytokine 
levels, and 2,891 for hsCRP levels. The mean follow-up duration was 5.5 years (s.d. 0.6 years). The 
number of participants with data from the psychiatric evaluation at follow-up was 2,833. Among these, 
258 participants were excluded due to missing information on inflammatory markers and 2 participants 
were excluded due to missing information on CVRFs. The resulting number of participants used to 
determine the association between inflammation at baseline and anxiety disorders at follow-up was 
2,573. The Institutional Ethics’ Committee of the University of Lausanne approved the CoLaus and the 
PsyCoLaus study. All participants provided written informed consent for the study protocol. 
 
Measurements 
Anxiety disorders and comorbid disorders 
Mental disorders at baseline and follow-up were assessed using the French version (Leboyer et al., 1995) 
of the semi-structured Diagnostic Interview for Genetic Studies (DIGS), which was developed and 
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validated by the National Institute of Mental Health (Nurnberger et al., 1994). The French version of this 
instrument (Leboyer et al., 1995) revealed adequate inter-rater reliability in terms of kappa and Yule’s 
coefficients for major mood and psychotic disorders (Preisig et al., 1999) as well as substance use 
disorders (Berney et al., 2002), whereas the 6-week test-retest reliability was slightly lower (Berney et 
al., 2002; Preisig et al., 1999). The DIGS was completed with sections on GAD, PTSD and phobia disorders 
using questions from the Schedule for Affective Disorders and Schizophrenia - Lifetime and Anxiety 
disorder version (SADS-LA (Endicott, & Spitzer, 1978)), which also revealed satisfactory test-retest 
reliability for panic disorder/agoraphobia (Yule's Y = 0.43), GAD (Yule's Y = 0.61) and phobic disorders 
(Yule's Y = 0.66). The Yule coefficient for the overall category of anxiety disorders was 0.49. (Leboyer et 
al., 1991). In our own reliability study, we found excellent or perfect inter-rater reliability for all specific 
anxiety disorders except for agoraphobia (Yule's Y = 0.96), whereas the 6-week test-retest reliability 
estimates were 0.58 for panic disorder, 0.55 for agoraphobia, 0.44 for social phobia and 0.77 for specific 
phobia. (Rougemont-Buecking et al., 2008). Interviewers were required to be masters-level 
psychologists and were trained over a two-month period. In order to provide ongoing supervision 
throughout the study, each interview and diagnostic assignment was reviewed by an experienced senior 
psychologist. Diagnoses were assigned according to the DSM-IV. Anxiety disorders included GAD, social 
phobia, panic disorder, agoraphobia, OCD and PTSD. For this study, anxiety disorders were defined as 
current if they were present at the time of the physical evaluation. 
 
Inflammatory markers 
HsCRP was assessed during baseline and follow-up physical evaluations using immunoassay and latex HS 
(IMMULITE 1000-High, Diagnostic Products Corporation, LA, CA, USA), with maximum intra- and 
interbatch coefficients of variation of 1.3% and 4.6%, respectively (Firmann et al., 2008). Subjects with a 
hsCRP level higher than 10 mg/l were excluded as an elevation of this magnitude is likely to be 
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attributable to acute infection (Pearson et al., 2003). For the baseline and follow-up cytokine 
measurements, serum was preferred to plasma, as it has been shown that different anticoagulants may 
differentially affect absolute cytokine levels (Skeppholm, Wallen, Blomback, & Kallner, 2008). Serum 
samples were stored at -80°C before assessment and sent on dry ice to the laboratory. Cytokine levels 
were measured using a multiplexed particle-based flow cytometric cytokine assay (Marques-Vidal et al., 
2011). Lower detection limits (LOD) for IL-6 and TNF-α were 0.2 pg/ml. Good agreement between signal 
and cytokine was found within the assay range (R
2 
≥ 0.99). 
 
Covariates 
Data were collected on age, race (Caucasian versus non-Caucasian), marital status (living alone versus 
living with someone) and health-related behaviors at baseline including smoking (never, former, 
current) and physical inactivity (no or low versus at least 20 minutes twice a week). Information on 
socio-economic status (SES) and on psychotropic drug treatment was derived from the DIGS. The level of 
SES was assessed using the Hollingshead scale (Hollingshead, 1975). The section on psychotropic drug 
treatment covered all antidepressants, mood stabilizers (lithium and anti-epileptics), antipsychotics and 
anxiolytics. Moreover, information on aspirin, statin and nonsteroidal anti-inflammatory use was 
collected during the baseline physical evaluation (never versus occasional versus regular use). The 
following biological variables were measured during the baseline physical evaluation: BMI (weight in 
kilograms divided by height in meters squared), diabetes (fasting blood glucose ≥ 7 mmol/l or treatment 
for diabetes), dyslipidemia (HDL-cholesterol < 1 mmol/l, or LDL-cholesterol ≥ 4.1 mmol/l, or triglycerides 
≥ 2.2 mmol/l, or treatment with a lipid-lowering drug), hypertension (systolic blood pressure ≥ 140 
mmHg or diastolic blood pressure ≥ 90 mmHg, or treatment for hypertension). 
 
Statistical analysis 
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Statistical analyses were conducted using the Statistical Analysis System (SAS Institute Inc., Cary, NC, 
USA), version 9.3 for Windows. Age was standardized. Descriptive data for demographic characteristics, 
comorbid disorders, medication, health-related behaviors, physical risk factors for CVD and 
inflammatory marker levels were derived by lifetime anxiety disorders, and Chi-square and Kruskal-
Wallis tests were used to determine the difference between anxiety disorders. The tests were two-tailed 
and p-values were not adjusted for multiple testing because the hypothesized associations between 
anxiety disorders and inflammatory markers were specified a priori. 
Associations between current and remitted anxiety disorders at baseline and levels of inflammatory 
markers at follow-up with adjustment for the respective levels at baseline were determined using 
multiple linear regression models. Because we adjusted 5-year inflammatory markers for the 
corresponding inflammatory marker level at baseline, the follow-up variables represent change scores 
(e.g., 5-year change in hsCRP). Box-Cox transformation was applied to the response variable whenever a 
deviation from fundamental assumptions was observed. Values below the LOD of 0.2 [pg/ml] (i.e., 5% of 
values for IL-6, 0.5% of values for TNF-α) were considered as censored observations. IL-6 and TNF-α 
were analyzed using the qualitative and limited dependent variable model (QLIM) with the threshold of -
1.65 [log (pg/ml)] as the meaningful lower bound of observed values. 
A multiple linear regression model was performed on log-transformed and standardized observed 
values. Two models of increasing complexity were computed. Model 1 included one single anxiety 
disorder (lifetime, current and remitted) at a time as the independent variable, adjusted for the 
corresponding inflammatory marker at baseline. Model 2 included current and remitted anxiety 
disorders simultaneously in order to determine the associations of specific anxiety disorder with 
inflammatory markers at follow-up, adjusting for the length of follow-up, sociodemographic 
characteristics (sex, age, SES, race and marital status), comorbid disorders (major depressive disorder, 
bipolar disorder and substance use disorders), medications (psychotropic medication, aspirin, statins 
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and nonsteroidal anti-inflammatories), health-related behaviors and physical risk factors for CVD at 
baseline and the covariate of Model 1. We did not adjust for steroid medications because of the low 
proportion of people taking immunosuppressants (n = 4) or steroid inhalers (n = 61). 
Associations between inflammatory markers at baseline and a history of anxiety disorders during the 
follow-up period were assessed using logistic regression models. Two models were computed. Model 1 
included all inflammatory markers simultaneously, adjusting for the corresponding history of anxiety 
disorder at baseline. Model 2 was further adjusted for the length of follow-up, sociodemographic 
characteristics, medications, health-related behaviors and physical risk factors for CVD.  
 
 
RESULTS 
Sample characteristics 
The description of the cohort of 3,113 participants used for the assessment of the prospective 
associations between anxiety disorders at baseline and the concentrations of inflammatory markers at 
follow-up is presented in Table 1. The groups (GAD, social phobia, panic disorder, agoraphobia, OCD, 
PTSD and no history of anxiety disorders) differed with respect to sex, SES, ethnicity, marital status, 
comorbid disorders (except for substance use disorders), psychotropic medication and BMI.  
HsCRP levels for current agoraphobia (median 1.05 [IQR 0.60-2.15]), remitted agoraphobia (0.95 [0.45-
2.05]) and no anxiety disorders (1.00 [0.50-2.10]) at baseline did not differ among the 3 groups (p-value 
= 0.781), whereas hsCRP levels for current agoraphobia (1.60 [0.70-3.35]), remitted agoraphobia (0.95 
[0.65-2.40]) and no anxiety disorders (1.10 [0.60-2.10]) at follow-up were statistically different among 
the 3 diagnostic groups (p-value = 0.023).  
Since no significant sex interactions were found, models were run for males and females together. 
Associations between anxiety disorders at baseline and inflammatory markers at follow-up 
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Associations between current and remitted anxiety disorders at baseline and levels of inflammatory 
markers at follow-up with adjustment for the respective level at baseline are presented in Table 2 and 3. 
When models were only adjusted for the corresponding inflammatory marker at baseline (Table 2), 
current anxiety disorders, as well as current agoraphobia were associated with a steeper increase of 
hsCRP levels over the follow-up period. In contrast, current PTSD was associated with a lower increase 
of IL-6 levels over the follow-up period. No significant associations were found for remitted anxiety 
disorders with inflammatory markers. When the model was further adjusted for potential confounders, 
including depression, current anxiety disorders were still significantly associated with hsCRP levels 
(Table 3). Moreover, current agoraphobia was associated with a steeper increase of hsCRP levels and 
remitted agoraphobia was newly associated with a steeper increase of TNF-α levels over the follow-up 
period in the fully adjusted model. Finally, the association between current PTSD and a lower increase of 
IL-6 levels over the follow-up period remained significant. 
 
Associations between inflammatory markers at baseline and anxiety disorders at follow-up 
Levels of the 3 inflammatory markers at baseline were not associated with any lifetime anxiety disorder 
at follow-up in either model (Table 4).  
We also tested the associations between inflammatory markers at baseline and incident cases of anxiety 
disorders excluding subjects that already had a lifetime history of these disorders at baseline. However, 
no significant associations were found (results not shown). 
 
 
DISCUSSION 
Based on a large adult cohort with comprehensive physical and psychiatric evaluations at baseline and 
follow-up, we found significant associations between current anxiety disorders in general, and current 
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agoraphobia specifically, at baseline with a steeper increase of hsCRP levels over a more than five year  
follow-up period. Moreover, current PTSD at baseline was associated with a lower increase of IL-6 levels 
over the follow-up period. These associations remained significant after adjustment for a 
comprehensive array of potential confounders, including major depressive disorder. No evidence was 
found for associations between the other anxiety disorder subtypes with any pro-inflammatory markers. 
 
Consistent with previous literature, anxiety disorders were associated with a steeper increase of hsCRP 
levels over the follow-up period after adjustment for multiple covariates (Liukkonen et al., 2006; 
Pitsavos et al., 2006; Vogelzangs, Beekman, de Jonge, & Penninx, 2013). Our further evaluation of 
specific subtypes of anxiety disorders that may explain this association revealed that the findings 
regarding hsCRP were specifically attributable to agoraphobia, confirming our previous analyses of 
lifetime anxiety disorders with inflammatory markers (Wagner et al., 2015). Similar to previous findings 
(Khandaker, Zammit, Lewis, & Jones, 2016; Pitsavos et al., 2006; Vogelzangs, Beekman, de Jonge, & 
Penninx, 2013), these results were not confounded by depressive disorders. The link between hsCRP and 
agoraphobia but not panic disorder may be attributable to the trait-like manifestations of agoraphobia 
versus the episodic fluctuations of panic attacks. 
 
To our knowledge, this study is the first to examine the association between inflammatory markers with 
the full range of anxiety disorder subtypes. Our findings do not confirm those of a recent cross-sectional 
population-based study that showed an association between GAD and increased CRP levels in 
adolescents (Khandaker, Zammit, Lewis, & Jones, 2016). However, the latter study did not adjust for the 
potentially confounding influences of psychotropic or inflammatory medications. Indeed, a prospective 
study of children found that the association between GAD and elevated CRP levels was mediated by 
health-related behaviors, such as BMI and medication (Copeland et al., 2012). Moreover, consistent with 
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our investigations, they found no association between CRP levels and subsequent GAD (Copeland et al., 
2012). This finding implies that inflammation may be a consequence of anxiety or its correlates, rather 
than the opposite. Our findings are also inconsistent with the only other study of a population-based 
sample of older adults that found that CRP was associated with increased psychosocial distress, 
including anxiety (Das, 2016). Therefore, future studies are needed to confirm our findings and to 
explore the potential mechanisms for this association. 
Our finding of a lower increase of IL-6 levels over the follow-up period in participants with PTSD at 
baseline is not consistent with results from several previous cross-sectional studies that showed either 
increased (Baker et al., 2001; von Kanel et al., 2010) or similar (Miller, Sutherland, Hutchison, & 
Alexander, 2001; Vidovic et al., 2011) levels of IL-6 in patients with PTSD compared to non-PTSD 
controls. Nevertheless, one previous study also revealed lower IL-6 levels in military veterans with 
lifetime history of PTSD than in their counterparts without PTSD, after adjustment for sociodemographic 
factors, health behaviors, traditional cardiovascular risk factors and medications (Plantinga et al., 2013). 
As IL-6 may also act as an anti-inflammatory cytokine through stimulation of the HPA axis, the authors of 
the study argued that low IL-6 levels could reflect long-term suppression of the anti-inflammatory IL-6 
response due to a hypersensitive HPA axis (Plantinga et al., 2013). In support of such reasoning, we 
found that current but not remitted PTSD was associated with lower IL-6 levels during the follow-up 
period compared to non-PTSD controls. 
 
Current, but not remitted, anxiety disorders in our sample were associated with a steeper increase of 
hsCRP levels over the follow-up period after adjustment for multiple covariates, while only remitted 
agoraphobia was associated with a steeper increase of TNF-α levels over the follow-up period. In cross-
sectional analyses, remitted agoraphobia at baseline was not associated with hsCRP levels at baseline, 
and the same for cross-sectional analyses at follow-up. Further analyses among the remitted 
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agoraphobia group at baseline (n = 34) showed that these participants had only one episode in their 
lifetime and the average time in remission was around 14.5 years (s.d. 9.8 years). For hsCRP, but not 
necessarily for TNF-α, these findings suggest that once anxiety has waned, inflammation may also 
decrease. Therefore, with respect to anxiety disorders, inflammation seems to be a ”scar” which may be 
persistent for a certain duration of time even after remission. However, after sufficient time, this “scar” 
may “heal”. Subsequently, future studies should investigate consequences of having had high 
inflammatory levels and the amount of agoraphobia remission time needed in order to “heal” and not to 
be anymore at increased risk of consequent cardiovascular diseases. Consequently, the anxiety status 
should be taken into consideration for the prevention and treatment of chronic inflammation. However, 
repeated assessments over time of different inflammatory markers would be needed to substantiate 
such a temporal relationship. Interestingly, in our previous cross-sectional analysis, anxiety disorders 
were associated with lower levels of hsCRP (Glaus et al., 2014). At the time, we suggested that this 
association may have been attributable to the low BMI of subjects with anxiety disorders (Glaus et al., 
2014). This may be less the case in this longitudinal study since we controlled for BMI. However, further 
longitudinal analysis of the associations between anxiety disorders and BMI and other measures of 
adiposity are needed to better elucidate these contradictory results. 
 
The finding of a prospective association of anxiety disorders with CRP in our study may provide one 
explanation for the link between anxiety and an increased risk of future coronary heart disease (CHD) 
and CVD mortality in the general population reported in a recent meta-analysis of more than two 
millions of participants (Emdin et al., 2016). The acute phase reactant CRP is arguably the most 
established circulating inflammatory biomarker of increased CVD (Vlachopoulos et al., 2015), which has 
been shown to add prognostic information on future CVD risk above and beyond the Framingham CHD 
risk score (Pearson et al., 2003). Regarding the clinical relevance of our findings, cut points of CRP for 
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low risk (<1.0 mg/L), average risk (1.0-3.0 mg/L), and high risk (>3.0 mg/L) of CHD have been defined, 
with the high-risk category showing a 2-fold higher relative risk of CHD than the low risk group (Pearson 
et al., 2003). Therefore, a 78% increase in the CRP median level in individuals with agoraphobia 
compared with the average CRP level in our cohort may seem a clinically meaningful difference in the 
relative risk of CHD.  
 
One candidate mechanism that may facilitate inflammation and elevated hsCRP in anxiety disorders is 
autonomic nervous system dysfunction as reflected in reduced heart rate variability (Chalmers, 
Quintana, Abbott, & Kemp, 2014) that is associated with heightened inflammation (Haensel et al., 2008). 
Although we did not investigate potential mechanisms, such as autonomic nervous system and HPA axis 
dysfunction, that might play a specific role in increased inflammation in agoraphobia as opposed to the 
other anxiety disorders, as noted above, these systems may be more chronically dysregulated in more 
stable conditions such as agoraphobia. As a consequence, sympathetic arousal and stress hormone 
production could be more sustained in agoraphobia through kindling of greater chronic low-grade 
inflammation (Elenkov, 2008). However, this remains speculative as, to our knowledge, systematic 
investigations on autonomic, neuroendocrine, and immune function in patients with agoraphobia 
(without panic disorder) in comparison with other anxiety disorders, including PTSD and OCD, have not 
previously been performed. 
 
Our results should be interpreted in the context of several limitations. First, there was an interval of 
almost one year between the physical and the psychiatric evaluations. Although the timing of anxiety 
episodes was elicited in our diagnostic interviews, we cannot exclude misclassification regarding the 
"current" status of disorders at the time of the physical evaluation. Second, similar to most prior studies, 
inflammatory markers were only assessed once at baseline and again at follow-up, and thus did not 
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reflect the dynamic changes of inflammatory markers over time. However, the majority of previous 
studies also collected only a single measure per assessment. Third, low-grade inflammation was 
measured by hsCRP and cytokine levels, but other potential biomarkers of inflammation, such as anti-
inflammatory cytokines and white blood cells were not included. Despite these limitations, this is one of 
the largest prospective studies of a community sample, with the hitherto longest follow-up period. It is 
the first study to investigate the full range of anxiety disorder subtypes, measuring both inflammatory 
markers and anxiety disorders at both times which design permitted us to disentangle some of the bi-
directional associations. Moreover, this study is the first that distinguished anxiety as a state versus a 
trait marker. To our knowledge, no previous studies looked at both current and remitted anxiety 
disorders in association with subsequent inflammation. 
 
 
CONCLUSION 
The results of this study suggest a direct association between current anxiety disorders at baseline and 
chronic low-grade inflammation at follow-up. In particular, current agoraphobia was prospectively 
associated with a steeper increase of hsCRP levels and PTSD was associated with a lower increase of IL-6 
levels over the follow-up period. Because anxiety disorders were prospectively associated with changes 
in these inflammatory markers that were not associated in remitted cases, these findings suggest that 
inflammation may be a consequence rather than risk factor for anxiety disorders. Further prospective 
studies with repeated assessments of inflammatory markers earlier in development are required to 
confirm potential mechanisms for the potential causal link between anxiety disorders and inflammation. 
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Table 1: Sociodemographic, Medication, Health-Related Behaviors, Physical Risk Factors for Cardiovascular Disorders and Inflammatory markers by lifetime 
anxiety disorders at baseline (n=3,113) 
 
Anxiety disorders 
 
GAD 
 
Social Phobia 
 
Panic Disorder 
 
Agoraphobia 
 
OCD 
 
PTSD 
 
No Anxiety 
 
p-value
a
 
 
n = 652 
 
n = 74 
 
n = 384 
 
n = 78 
 
n = 116 
 
n = 43 
 
n = 118 
 
n = 2461 
 
 
Current n = 412 
 
Current n = 39 
 
Current n = 255 
 
Current n = 34 
 
Current n = 82 
 
Current n = 22 
 
Current n = 50 
   
 
Remitted n = 240 
 
Remitted n = 35 
 
Remitted n = 129 
 
Remitted n = 44 
 
Remitted n = 34 
 
Remitted n = 21 
 
Remitted n = 68 
   Sociodemographics 
                         Length of follow-up [years], mean (SD) 5.49 (0.62) 
 
5.53 (0.62) 
 
5.53 (0.63) 
 
5.53 (0.57) 
 
5.47 (0.61) 
 
5.47 (0.59) 
 
5.46 (0.59) 
 
5.53 (0.61) 
 
0.439
b
 
Sex, n (%) 
                         
Female 427 (65.49) 
 
47 (63.51) 
 
243 (63.28) 
 
57 (73.08) 
 
90 (77.59) 
 
29 (67.44) 
 
82 (69.49) 
 
1245 (50.59) 
 <.0001 
Male 225 (34.51) 
 
27 (36.49) 
 
141 (36.72) 
 
21 (26.92) 
 
26 (22.41) 
 
14 (32.56) 
 
36 (30.51) 
 
1216 (49.41) 
 
Age [years], mean (SD) 50.69 (8.70) 
 
53.02 (8.87) 
 
50.06 (8.64) 
 
50.72 (8.81) 
 
51.96 (8.54) 
 
48.60 (9.15) 
 
51.08 (8.82) 
 
51.08 (8.85) 
 
0.173
b
 
Socio-economic status
c
, mean (SD) 3.31 (1.27) 
 
3.19 (1.35) 
 
3.33 (1.24) 
 
3.22 (1.26) 
 
3.17 (1.29) 
 
3.37 (1.33) 
 
3.08 (1.35) 
 
3.45 (1.27) 
 
0.037
b
 
Ethnicity, n (%) 
                         
Caucasian 611 (93.71) 
 
70 (94.59) 
 
362 (94.27) 
 
73 (93.59) 
 
114 (98.28) 
 
42 (97.67) 
 
103 (87.29) 
 
2265 (92.04) 
 0.014 
Other 41 (6.29) 
 
4 (5.41) 
 
22 (5.73) 
 
5 (6.41) 
 
2 (1.72) 
 
1 (2.33) 
 
15 (12.71) 
 
196 (7.96) 
 
Marital status, n (%) 
                         
Living alone 252 (38.65) 
 
25 (33.78) 
 
148 (38.54) 
 
23 (29.49) 
 
45 (38.79) 
 
21 (48.84) 
 
50 (42.37) 
 
748 (30.39) 
 0.004 
Living in couple 400 (61.35) 
 
49 (66.22) 
 
236 (61.46) 
 
55 (70.51) 
 
71 (61.21) 
 
22 (51.16) 
 
68 (57.63) 
 
1713 (69.61) 
 
Comorbid disorders, n (%) 
                         
Bipolar Disorders 24 (3.68) 
 
5 (6.76) 
 
16 (4.17) 
 
1 (1.28) 
 
5 (4.31) 
 
4 (9.30) 
 
4 (3.39) 
 
30 (1.22) 
 
0.000 
Major Depressive disorders 402 (61.66) 
 
49 (66.22) 
 
235 (61.20) 
 
47 (60.26) 
 
65 (56.03) 
 
27 (62.79) 
 
88 (74.58) 
 
963 (39.13) 
 
<.0001 
Atypical MDD 63 (9.66) 
 
4 (5.41) 
 
38 (9.90) 
 
2 (2.56) 
 
10 (8.62) 
 
1 (2.33) 
 
17 (14.41) 
 
142 (5.77) 
 
0.001 
Substance use disorders 105 (16.10) 
 
9 (12.16) 
 
60 (15.63) 
 
10 (12.82) 
 
17 (14.66) 
 
10 (23.26) 
 
29 (24.58) 
 
364 (14.79) 
 
0.065 
Medication, n (%) 
                         
Antidipressants 217 (33.28) 
 
31 (41.89) 
 
121 (31.51) 
 
30 (38.46) 
 
44 (37.93) 
 
23 (53.49) 
 
43 (36.44) 
 
421 (17.11) 
 
<.0001 
Mood stabilizers 11 (1.69) 
 
4 (5.41) 
 
3 (0.78) 
 
1 (1.28) 
 
4 (3.45) 
 
2 (4.65) 
 
2 (1.69) 
 
10 (0.41) 
 
0.003 
Antipsychotics 27 (4.14) 
 
5 (6.76) 
 
14 (3.65) 
 
6 (7.69) 
 
8 (6.90) 
 
5 (11.63) 
 
6 (5.08) 
 
23 (0.93) 
 
<.0001 
Anxiolytics 273 (41.9)  42 (56.8)  139 (36.2)  46 (59.0)  71 (61.2)  22 (51.2)  59 (50.0)  540 (21.9)  <.0001 
Aspirin 58 (8.90) 
 
9 (12.16) 
 
26 (6.77) 
 
6 (7.69) 
 
10 (8.62) 
 
4 (9.30) 
 
12 (10.17) 
 
202 (8.21) 
 
0.963 
Statins 55 (8.44) 
 
7 (9.46) 
 
28 (7.29) 
 
10 (12.82) 
 
15 (12.93) 
 
3 (6.98) 
 
11 (9.32) 
 
176 (7.15) 
 
0.172 
NSAIDs 107 (16.41)  10 (13.51)  59 (15.36)  12 (15.38)  26 (22.41)  5 (11.6)  15 (12.7)  384 (15.6)  0.472 
Health-related behaviors, n (%) 
                         
Former smoking 231 (35.43) 
 
31 (41.89) 
 
126 (32.81) 
 
30 (38.46) 
 
49 (42.24) 
 
10 (23.26) 
 
42 (35.59) 
 
798 (32.43) 
 
0.195 
Current smoking 176 (26.99) 
 
15 (20.27) 
 
102 (26.56) 
 
20 (25.64) 
 
31 (26.72) 
 
17 (39.53) 
 
40 (33.90) 
 
683 (27.75) 
 
0.285 
Physical inactivity 293 (44.94) 
 
29 (39.19) 
 
165 (42.97) 
 
39 (50.00) 
 
59 (50.86) 
 
16 (37.21) 
 
59 (50.00) 
 
1063 (43.19) 
 
0.334 
Biological risk factors 
                         
Body mass index, mean (SD) 24.94 (4.41) 
 
25.74 (4.22) 
 
24.64 (4.19) 
 
24.90 (5.03) 
 
24.99 (4.65) 
 
23.89 (3.92) 
 
25.86 (4.84) 
 
25.44 (4.34) 
 
0.004
b
 
Diabetes, n (%) 33 (5.06) 
 
5 (6.76) 
 
17 (4.43) 
 
2 (2.56) 
 
10 (8.62) 
 
3 (6.98) 
 
5 (4.24) 
 
115 (4.67) 
 
0.169 
Dyslypidemia, n (%) 194 (29.75) 
 
27 (36.49) 
 
115 (29.95) 
 
26 (33.33) 
 
36 (31.03) 
 
8 (18.60) 
 
36 (30.51) 
 
795 (32.30) 
 
0.141 
Hypertension, n (%) 174 (26.69) 
 
23 (31.08) 
 
95 (24.74) 
 
24 (30.77) 
 
41 (35.34) 
 
4 (9.30) 
 
31 (26.27) 
 
727 (29.54) 
 
0.037 
Inflammatory markers at baseline, Median (IQR) 
                       
Interleukin-6 1.22 (0.50-3.11) 
 
1.28 (0.74-3.20) 
 
1.08 (0.45-3.12) 
 
1.28 (0.70-3.43) 
 
1.25 (0.49-3.62) 
 
0.81 (0.40-2.34) 
 
1.35 (0.73-3.11) 
 
1.28 (0.56-3.17) 
 
0.219 
Tumor Necrosis Factor-α 2.65 (1.63-4.41) 
 
3.28 (2.01-4.60) 
 
2.70 (1.62-4.49) 
 
2.56 (1.55-4.66) 
 
2.50 (1.69-4.40) 
 
2.43 (1.78-3.90) 
 
2.60 (1.61-4.04) 
 
2.82 (1.79-4.39) 
 
0.271 
High-sensitivity C-Reactive protein 1.00 (0.50-2.10) 
 
1.20 (0.60-3.00) 
 
0.90 (0.40-1.90) 
 
0.90 (0.50-1.70) 
 
1.00 (0.50-2.15) 
 
0.60 (0.30-1.70) 
 
1.10 (0.50-2.50) 
 
1.00 (0.50-2.10) 
 
0.130 
Inflammatory markers at follow-up, Median (IQR) 
                       
Interleukin-6 2.41 (0.92-7.30) 
 
1.95 (0.79-5.61) 
 
2.48 (0.88-8.25) 
 
2.40 (0.89-8.05) 
 
3.01 (1.05-8.09) 
 
2.36 (0.90-8.75) 
 
2.06 (0.87-6.56) 
 
2.53 (0.93-8.44) 
 
0.693 
Tumor Necrosis Factor-α 4.66 (2.56-8.49) 
 
4.46 (2.76-8.66) 
 
4.75 (2.58-8.83) 
 
4.32 (2.82-7.43) 
 
4.76 (2.98-9.21) 
 
4.09 (1.89-6.71) 
 
4.00 (1.88-9.36) 
 
4.56 (2.44-8.00) 
 
0.768 
High-sensitivity C-Reactive protein 1.1 (0.60-2.40) 
 
1.50 (0.70-2.30) 
 
1.00 (0.60-2.35) 
 
0.90 (0.40-1.90) 
 
1.50 (0.70-3.15) 
 
0.80 (0.40-1.60) 
 
1.20 (0.70-2.40) 
 
1.10 (0.60-2.10) 
 
0.051 
Abbreviations: SD = standard deviation; GAD = Generalized Anxiety Disorder; MDD = Major Depressive Disorder; OCD = Obsessive-Compulsive Disorder; PTSD = Post-Traumatic Stress Disorder; 
IQR=Interquartile range (the 25% and 75% are provided); NSAIDs = Nonsteroidal anti-inflammatories  
Median and IQR of inflammatory markers were not logarithmically transformed (n IL-6, TNF-α = 2791, n hsCRP = 2891). 
a
 Chi-square Test; 
b
 Kruskal-Wallis Test; 
c
 A value of 3 represents a socio-economic status of III (middle class) on the Hollingshead scale. 
  
Page 21 of 26 Depression and Anxiety
Glaus - 22 
 
 
 
 
 
TABLE 2: Associations between current and remitted anxiety disorders at baseline and inflammatory markers at follow-up 
 
Interleukin 6 [pg/ml] 
 
Tumor Necrosis Factor-α [pg/ml] 
 
hs C-Reactive Protein [mg/l] 
 
β
a
 (95% CI) p-value 
 
β
a
 (95% CI) p-value 
 
β
a
 (95% CI) p-value 
Current diagnoses 
   
Anxiety disorders -0.05 (-0.22-0.12) 0.572 
 
0.05 (-0.06-0.16) 0.387 
 
0.08 (-0.01-0.16) 0.069 
Generalized Anxiety Disorder -0.30 (-0.83-0.24) 0.274 
 
-0.13 (-0.47-0.20) 0.436 
 
-0.00 (-0.26-0.25) 0.971 
Social Phobia 0.00 (-0.21-0.22) 0.963 
 
0.07 (-0.07-0.20) 0.314 
 
0.08 (-0.02-0.18) 0.129 
Panic Disorder -0.02 (-0.58-0.54) 0.937 
 
-0.15 (-0.50-0.20) 0.390 
 
-0.14 (-0.40-0.12) 0.292 
Agoraphobia 0.01 (-0.36-0.38) 0.959 
 
0.12 (-0.11-0.35) 0.289 
 
0.24 (0.07-0.42) 0.005 
Obsessive-Compulsive Disorder -0.29 (-1.00-0.41) 0.419 
 
-0.35 (-0.79-0.09) 0.116 
 
0.10 (-0.23-0.43) 0.550 
Post-Traumatic Stress Disorder -0.57 (-1.04/-0.10) 0.018 0.02 (-0.27-0.31) 0.885 0.00 (-0.22-0.22) 0.992 
Remitted diagnoses 
           
Anxiety disorders 0.14 (-0.08-0.36) 0.211 
 
0.02 (-0.12-0.16) 0.778 
 
0.05 (-0.05-0.15) 0.330 
Generalized Anxiety Disorder -0.28 (-0.82-0.27) 0.319 
 
0.06 (-0.28-0.39) 0.745 
 
0.09 (-0.18-0.37) 0.515 
Social Phobia 0.17 (-0.12-0.46) 0.241 
 
-0.01 (-0.19-0.17) 0.945 
 
0.06 (-0.07-0.20) 0.365 
Panic Disorder -0.04 (-0.57-0.50) 0.890 
 
0.09 (-0.24-0.43) 0.580 
 
0.02 (-0.20-0.25) 0.843 
Agoraphobia 0.13 (-0.43-0.69) 0.657 
 
0.35 (-0.00-0.69) 0.052 
 
0.04 (-0.23-0.30) 0.779 
Obsessive-Compulsive Disorder 0.26 (-0.48-1.01) 0.490 
 
-0.12 (-0.58-0.35) 0.618 
 
-0.24 (-0.56-0.09) 0.150 
Post-Traumatic Stress Disorder 0.04 (-0.38-0.47) 0.841 0.00 (-0.26-0.27) 0.976 -0.02 (-0.21-0.17) 0.806 
 Abbreviations: β = β-estimator; CI = confidence interval. 
Models adjusted for the corresponding inflammatory marker at baseline. 
ᵃ Multiple regression with logarithmically transformed cytokine (n = 2791) or hsCRP concentrations (n = 2891). 
Statistically significant results are in bold. 
p-values are in italic. 
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Table 3: Adjusted associations between current and remitted anxiety disorders at baseline and inflammatory markers at follow-up 
 
Interleukin 6 [pg/ml] 
 
Tumor Necrosis Factor-α [pg/ml] 
 
hs C-Reactive Protein [mg/l] 
 
β
a
 (95% CI) p-value 
 
β
a
 (95% CI) p-value 
 
β
a
 (95% CI) p-value 
Current Diagnoses 
 
Anxiety disorders -0.03 (-0.21-0.16) 0.783 
 
0.06 (-0.05-0.18) 0.280 
 
0.09 (0.00-0.17) 0.040 
Generalized Anxiety Disorder -0.26 (-0.80-0.28) 0.349 
 
-0.21 (-0.55-0.13) 0.228 
 
-0.03 (-0.29-0.23) 0.827 
Social Phobia 0.02 (-0.20-0.25) 0.827 0.10 (-0.04-0.24) 0.154 0.10 (-0.01-0.20) 0.064 
Panic Disorder -0.02 (-0.61-0.56) 0.943 -0.28 (-0.65-0.08) 0.127 -0.25 (-0.53-0.02) 0.067 
Agoraphobia 0.07 (-0.31-0.45) 0.720 0.15 (-0.09-0.39) 0.222 0.25 (0.07-0.43) 0.005 
Obsessive Compulsive Disorder -0.16 (-0.88-0.56) 0.664 -0.40 (-0.85-0.05) 0.079 0.05 (-0.29-0.39) 0.766 
Post-Traumatic Stress Disorder -0.52 (-1.00/-0.04) 0.033 0.06 (-0.23-0.36) 0.676 -0.04 (-0.26-0.19) 0.738 
Remitted Diagnoses 
           
Anxiety disorders 0.16 (-0.06-0.39) 0.158 
 
0.04 (-0.10-0.18) 0.598 
 
0.08 (-0.03-0.18) 0.153 
Generalized Anxiety Disorder -0.27 (-0.82-0.28) 0.338 
 
0.07 (-0.28-0.41) 0.704 
 
0.06 (-0.21-0.34) 0.645 
Social Phobia 0.20 (-0.09-0.49) 0.185 0.01 (-0.17-0.19) 0.943 0.09 (-0.05-0.22) 0.216 
Panic Disorder -0.09 (-0.63-0.46) 0.755 0.00 (-0.34-0.34) 0.977 -0.00 (-0.23-0.23) 0.982 
Agoraphobia 0.15 (-0.43-0.73) 0.613 0.42 (0.06-0.78) 0.024 0.09 (-0.18-0.36) 0.498 
Obsessive Compulsive Disorder 0.25 (-0.50-1.01) 0.515 -0.13 (-0.60-0.34) 0.577 -0.18 (-0.51-0.14) 0.275 
Post-Traumatic Stress Disorder 0.07 (-0.36-0.50) 0.749 0.01 (-0.26-0.27) 0.962 -0.05 (-0.24-0.14) 0.577 
Abbreviations: β = β-estimator; CI = confidence interval. 
Models adjusted for the corresponding inflammatory marker at baseline, length of follow-up, socio-demographic variables (age, gender and socio-
economic status), comorbid disorders (mood and substance use disorders), medications (antidepressants, mood stabilizers, antipsychotics, anxiolytics, 
aspirin, statin, nonsteroidal anti-inflammatories), behavioral cardiovascular risk factors (physical activity and smoking status) and physical cardiovascular 
risk factors (BMI, diabetes, hypertension and dyslipidemia) at baseline. 
ᵃ Multiple regression with logarithmically transformed cytokine (n = 2791) or hsCRP concentrations (n = 2891). 
Statistically significant results are in bold. 
p-values are in italic. 
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Table 4: Associations between inflammatory markers at baseline and anxiety disorders at follow-up (n=2,573) 
Levels of 
Inflammatory 
marker at 
baseline 
Anxiety Disorders 
 
GAD 
 
Social Phobia 
 
Panic Disorder 
 
Agoraphobia 
 
OCD 
 
PTSD 
n = 186 
 
n = 48 
 
n = 85 
 
n = 21 
 
n = 45 
 
n = 14 
 
n = 14 
OR (95% CI) p-value 
 
OR (95% CI) p-value 
 
OR (95% CI) p-value 
 
OR (95% CI) p-value 
 
OR (95% CI) p-value 
 
OR (95% CI) p-value 
 
OR (95% CI) p-value 
Model 1 
                   
        IL-6 [pg/ml] 1.09 (0.94-1.28) 0.257 
 
1.21 (0.91-1.59) 0.184 
 
1.23 (0.98-1.55) 0.070 
 
0.87 (0.56-1.37) 0.557 
 
0.80 (0.57-1.12) 0.184 
 
0.83 (0.47-1.47) 0.526 
 
0.98 (0.57-1.66) 0.925 
TNF-α [pg/ml] 1.10 (0.95-1.27) 0.192 
 
1.02 (0.77-1.36) 0.884 
 
1.11 (0.91-1.37) 0.302 
 
0.98 (0.63-1.53) 0.920 
 
0.92 (0.68-1.26) 0.602 
 
0.92 (0.54-1.57) 0.752 
 
1.07 (0.64-1.79) 0.792 
hsCRP [mg/l] 0.98 (0.84-1.14) 0.766 
 
0.89 (0.67-1.20) 0.450 
 
0.99 (0.78-1.24) 0.908 
 
1.07 (0.70-1.65) 0.752 
 
0.88 (0.64-1.20) 0.422 
 
0.93 (0.55-1.55) 0.771 
 
1.42 (0.84-2.42) 0.192 
Model 2 
                   
 
      
 IL-6 [pg/ml] 1.05 (0.89-1.25) 0.576 
 
1.25 (0.93-1.67) 0.142 
 
1.16 (0.89-1.50) 0.267 
 
0.88 (0.54-1.44) 0.604 
 
0.76 (0.52-1.10) 0.145 
 
0.84 (0.45-1.58) 0.595 
 
0.88 (0.47-1.62) 0.671 
TNF-α [pg/ml] 1.06 (0.90-1.25) 0.459 
 
1.02 (0.76-1.37) 0.892 
 
1.04 (0.82-1.32) 0.767 
 
0.98 (0.60-1.61) 0.942 
 
0.94 (0.66-1.31) 0.722 
 
0.97 (0.54-1.76) 0.928 
 
1.13 (0.64-2.00) 0.683 
hsCRP [mg/l] 0.99 (0.83-1.19) 0.935 
 
0.99 (0.71-1.37) 0.937 
 
1.06 (0.81-1.40) 0.662 
 
0.98 (0.61-1.57) 0.922 
 
0.90 (0.62-1.32) 0.601 
 
0.91 (0.51-1.62) 0.745 
 
1.28 (0.71-2.32) 0.408 
Abbreviations: IL-6 = Interleukin-6; TNF-α = Tumor Necrosis Factor-α; hsCRP = high sensitivity C-Reactive Protein; GAD = Generalized Anxiety Disorder; OR = odds ratio; CI = confidence 
interval. 
Model 1: adjusted for the corresponding anxiety disorder at baseline. 
Model 2: adjusted for the corresponding anxiety disorder at baseline, length of follow-up, socio-demographic variables (gender, age, socio-economic status, ethnicity and marital status), 
medications (antidepressants, mood stabilizers, antipsychotics, anxiolytics, aspirin, statin, nonsteroidal anti-inflammatories), health-related behaviors (former smoker, current smoker and 
physical inactivity), and physical cardiovascular risk factors (body mass index, diabetes, dyslipidemia and hypertension) at baseline. 
p-values are in italic. 
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FIGURE LEGEND 
Figure 1. Flow chart of the study for the association between anxiety disorders at baseline and 
inflammatory markers at follow-up and for the association between inflammatory markers at baseline 
and anxiety disorders at follow-up. Abbreviation: hsCRP, high-sensitivity C-Reactive Protein.      Baseline 
assessment;       Follow-up assessment for the association between anxiety disorders at baseline and 
inflammatory markers at follow-up;      Follow-up sample for the association between inflammatory 
markers at baseline and anxiety disorders at follow-up. 
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Figure 1. Flow chart of the study for the association between anxiety disorders at baseline and inflammatory 
markers at follow-up and for the association between inflammatory markers at baseline and anxiety 
disorders at follow-up. Abbreviation: hsCRP, high-sensitivity C-Reactive Protein. Baseline assessment; 
Follow-up assessment for the association between anxiety disorders at baseline and inflammatory markers 
at follow-up; Follow-up sample for the association between inflammatory markers at baseline and anxiety 
disorders at follow-up.  
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